Jim Cramer has expressed his confidence in Eli Lilly and Co (NYSE:LLY), citing the company’s diverse drug portfolio and the recent endorsement of its Alzheimer’s treatment by FDA advisors. What Happened: Cramer, the host of CNBC’s “Mad Money,” has been a long-time supporter of Eli Lilly. He believes that the company’s success in the weight loss and diabetes drug markets, combined with the potential of its new Alzheimer’s treatment, could propel its valuation to a trillion dollars, reported CNBC on Tuesday. “Right now, Eli Lilly’s an $823 billion behemoth, and I truly believe it’s ultimately he…
